ARQT Live signals | Maximize Profits with Getagraph.com

BUY 51300 min ago

@ $12.30

Issued: 11 Apr 2024 @ 12:30

Return: -25.85%

Previous signal: Apr 11 - 10:25

Previous signal: Sell

Return: -0.89 %

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 16:00):

Stats
Today's Volume	4.30M
Average Volume	3.80M
Market Cap	1.06B
EPS	$0 ( 2024-05-14 )
Next earnings date	( $-0.730 ) 2024-06-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.41
ATR14	$0.0210 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Moore Matthew Richard	Buy	4 166	Common Stock
2024-05-02	Moore Matthew Richard	Sell	4 681	Common Stock
2024-05-02	Watanabe Todd Franklin	Sell	13 783	Common Stock
2024-05-02	Matsuda Masaru	Sell	5 016	Common Stock
2024-05-02	Burnett Patrick	Sell	9 555	Common Stock

INSIDER POWER
30.18
Last 98 transactions
Buy: 3 263 487 \| Sell: 1 661 615

Volume Correlation

Long: -0.33 (neutral)

Short: -0.18 (neutral)

Signal:(37.005) Neutral

Arcutis Biotherapeutics Correlation

10 Most Positive Correlations
KRTX	0.952
UCTT	0.95
LRCX	0.941
ECHO	0.94
LCUT	0.936
META	0.934
LRGE	0.934
SMCI	0.932
DEMZ	0.931
FTC	0.931

10 Most Negative Correlations
RMRM	-0.948
CYXT	-0.946
SGLB	-0.945
DSWL	-0.94
LSAQ	-0.937
SRNGW	-0.931
BIOL	-0.929
SOLO	-0.929
ENNV	-0.928
TCFC	-0.925

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arcutis Biotherapeutics Correlation - Currency/Commodity

0.25
( neutral )

0.39
( neutral )

0.00
( neutral )

-0.13
( neutral )

-0.75
( moderate negative )

-0.09
( neutral )

Arcutis Biotherapeutics Financials

Annual	2023
Revenue:	$59.61M
Gross Profit:	$53.49M (89.74 %)
EPS:	$-3.78

FY	2023
Revenue:	$59.61M
Gross Profit:	$53.49M (89.74 %)
EPS:	$-3.78

FY	2022
Revenue:	$3.69M
Gross Profit:	$2.93M (79.54 %)
EPS:	$-5.84

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-5.79

Financial Reports:

No articles found.

Arcutis Biotherapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.